WIP
CASI

Wellesley Investment Partners’s CASI Pharmaceuticals CASI Stock Holding History

Wellesley Investment Partners’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,500
Closed -$30K – 104
2020
Q1 		$30K Buy
+1,500
New +$35.8K 0.01% 102

Other funds holding CASI

IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellesley Investment Partners's CASI Position: Q2 2020 in Review

Wellesley Investment Partners sold out of CASI Pharmaceuticals (CASI) in Q2 2020, closing a stake of 1,500 shares — an estimated $30K sold.

Wellesley Investment Partners first reported a position in CASI in Q1 2020 and held it in 1 quarter. The position peaked at $30K in Q1 2020. 59 funds tracked by Wall St. Rank hold CASI as of Q2 2020.

  • Wellesley Investment Partners reported no remaining CASI Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Wellesley Investment Partners sold 1,500 CASI Pharmaceuticals shares in Q2 2020, an estimated $30K.
  • Wellesley Investment Partners first reported a position in CASI Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Wellesley Investment Partners's CASI Pharmaceuticals position peaked at $30K in Q1 2020.
  • 59 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2020.

Based on Wellesley Investment Partners's 13F filing for Q2 2020, filed 12 Aug 2020.